![]() Tixagevimab (teal, right) and cilgavimab (purple, left) binding the spike protein RBD. From PDB: 7L7E. | |
Combination of | |
---|---|
Tixagevimab | Monoclonal antibody |
Cilgavimab | Monoclonal antibody |
Clinical data | |
Trade names | Evusheld |
Other names | AZD7442 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a621058 |
License data |
|
Pregnancy category | |
Routes of administration | Intramuscular |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Clinical data | |
---|---|
Drug class | Antiviral |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6488H10034N1746O2038S50 |
Molar mass | 146706.82 g·mol−1 |
Clinical data | |
---|---|
Drug class | Antiviral |
ATC code |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6626H10218N1750O2078S44 |
Molar mass | 149053.44 g·mol−1 |
Tixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS-CoV-2[14][15] used to prevent COVID-19.[16] It is being developed by British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca.[17][18] It is co-packaged and given as two separate consecutive intramuscular injections (one injection per monoclonal antibody, given in immediate succession).[19]